Azuma A, Hanaoka K, Kurihara A, Kobayashi T, Miyauchi S, Kamo N, Tanaka M, Sasaki T, Matsuda A
Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
J Med Chem. 1995 Aug 18;38(17):3391-7. doi: 10.1021/jm00017a023.
We have designed 2'-C-cyano-2'-deoxy-1-beta-D-arabino- pentofuranosylcytosine (CNDAC) as a potential mechanism-based DNA-strand-breaking nucleoside, which showed potent tumor cell growth inhibitory activity against various human tumor cell lines in vitro and in vivo. When measuring the pKa of the 2' alpha-proton of CNDAC, we found that CNDAC epimerized to 2'-C-cyano-2'-deoxy-1-beta-D-ribo-pentofuranosylcytosine (CNDC) with concomitant degradation of both CNDAC and CNDC to cytosine and 1,4-anhydro-2-C-cyano-2-deoxy-D-erythro-pent-1- enitol. Kinetic analysis of these reactions showed that abstraction of the acidic 2'-proton of CNDAC and CNDC initiated the reactions, which quickly reached an equilibrium. In the equilibrium, a concentration ratio of CNDAC and CNDC was about 3:5. Concomitant degradation of these nucleosides was found to be rather slow. Deuterium incorporation experiments with CNDAC in a D2O buffer suggested the mechanism of the beta-elimination reactions is an E1cB type. These epimerization and degradation reactions were found even in neutral conditions (pH 7.5) and also occurred in RPMI 1640 cell culture medium. The discovery of which nucleoside possesses the predominate tumor cell growth inhibitory activity was important. While both nucleosides showed potent tumor cell growth inhibitory activity against three human tumor cell lines (colon carcinoma WiDr, small cell lung carcinoma SBC-5, and stomach carcinoma MKN-74 cells) in 48 h of incubation, in 20 min of incubation, CNDAC was 11-50 times more effective than CNDC. In vivo antileukemic activity of these nucleosides against a mouse P388 model, CNDAC was obviously superior to CNDC.(ABSTRACT TRUNCATED AT 250 WORDS)
我们设计了2'-C-氰基-2'-脱氧-1-β-D-阿拉伯呋喃糖基胞嘧啶(CNDAC)作为一种潜在的基于机制的DNA链断裂核苷,它在体外和体内对多种人类肿瘤细胞系均表现出强大的肿瘤细胞生长抑制活性。在测量CNDAC的2'α-质子的pKa时,我们发现CNDAC差向异构化为2'-C-氰基-2'-脱氧-1-β-D-核糖呋喃糖基胞嘧啶(CNDC),同时CNDAC和CNDC均降解为胞嘧啶和1,4-脱水-2-C-氰基-2-脱氧-D-赤藓戊-1-烯醇。对这些反应的动力学分析表明,CNDAC和CNDC的酸性2'-质子的夺取引发了反应,反应迅速达到平衡。在平衡状态下,CNDAC和CNDC的浓度比约为3:5。发现这些核苷的伴随降解相当缓慢。在D2O缓冲液中用CNDAC进行的氘掺入实验表明,β-消除反应的机制是E1cB型。即使在中性条件(pH 7.5)下也发现了这些差向异构化和降解反应,并且它们也发生在RPMI 1640细胞培养基中。确定哪种核苷具有主要的肿瘤细胞生长抑制活性很重要。虽然两种核苷在孵育48小时后对三种人类肿瘤细胞系(结肠癌细胞WiDr、小细胞肺癌细胞SBC-5和胃癌细胞MKN-74)均表现出强大的肿瘤细胞生长抑制活性,但在孵育20分钟时,CNDAC的效果比CNDC强11至50倍。在针对小鼠P388模型的体内抗白血病活性方面,CNDAC明显优于CNDC。(摘要截短至250字)